Associations - ALK mutation

ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	ALK inhibitor Sensitive: C3 – Early Trials ALK inhibitor Sensitive : C3	ALK inhibitor Sensitive: C3 – Early Trials ALK inhibitor Sensitive : C3
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	crizotinib + alectinib Sensitive: C3 – Early Trials crizotinib + alectinib Sensitive : C3	crizotinib + alectinib Sensitive: C3 – Early Trials crizotinib + alectinib Sensitive : C3
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3
ALK mutation	Melanoma	ALK mutation	Melanoma	entrectinib Resistant: C4 – Case Studies entrectinib Resistant : C4	entrectinib Resistant: C4 – Case Studies entrectinib Resistant : C4
ALK mutation	Melanoma	ALK mutation	Melanoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	crizotinib + TNO155 Sensitive: D – Preclinical crizotinib + TNO155 Sensitive : D	crizotinib + TNO155 Sensitive: D – Preclinical crizotinib + TNO155 Sensitive : D
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	ceritinib + TNO155 Sensitive: D – Preclinical ceritinib + TNO155 Sensitive : D	ceritinib + TNO155 Sensitive: D – Preclinical ceritinib + TNO155 Sensitive : D
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	lorlatinib + TNO155 Sensitive: D – Preclinical lorlatinib + TNO155 Sensitive : D	lorlatinib + TNO155 Sensitive: D – Preclinical lorlatinib + TNO155 Sensitive : D

Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.